Hepa1-6-hPD-L1
Strain Information
Validation Data
1. In vitro Expression of Hepa1-6-hPDL1 cell line
The hPDL1 protein expression in the Hepa1-6-hPDL1 cells were measured by Flow Cytometry. FACS data showed that significant human PDL1 expression in the Hepa1-6-hPDL1 cell line.
Figure 1. hPDL1 expression in Hepa1-6-hPDL1 cell line
2. Characterization of in vivo growth kinetics
To test the take rates, and the tumor growth characteristics of Hepa1-6-hPDL1 cell line, cells were subcutaneously inoculated into the C57BL/6 mice. The tumor growth curve was shown in the Fig 2.
Figure 2. Tumor growth curve of Hepa1-6-hPDL1 syngeneic model (n=4)
Figure 3. Body weight change of Hepa1-6-hPDL1 syngeneic model (n=4)
3. Expression of hPDL1 protein in tumors
To verify the hPDL1 protein expression, the tumors were dissected and seperated for single cell suspension. Human PDL1 protein expression can be detected in the humanized modified tumors.
Figure 4. The expression of hPDL1 in humanized modified tumors by FACS
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreAt GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
